N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 / Phase 3 ClinicalTrials.gov

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Sponsor: National Cancer Institute (NCI) • ClinicalTrials.gov ID: NCT05058651

Registry updated: 2026-10-22
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.

Interventions

  • Atezolizumab (Biological)
    Given IV
  • Biospecimen Collection (Procedure)
    Undergo blood sample collection
  • Carboplatin (Drug)
    Given IV
  • Cisplatin (Drug)
    Given IV
  • Computed Tomography (Procedure)
    Undergo CT scan
  • Etoposide (Drug)
    Given IV
  • Magnetic Resonance Imaging (Procedure)
    Undergo MRI
  • Patient Observation (Other)
    Undergo observation

Eligibility criteria

Inclusion Criteria: * Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC) * Participants must have disease that is unresectable or metastatic and not eligible for definitive therapy as deemed per the treating investigator * Participants must have radiologically evaluable disease, measurable or non-measurable, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if contraindication to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form * Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for brain metastases. Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply: * Participants who have received treatment for brain metastases must have: * No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration * Discontinued all corticosteroids at least 14 days prior to registration * Participants with treatment-naive brain lesions must have: * No lesion measuring \> 2.0 cm in size in any axis * MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration * No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration * No need for \> 2 mg of dexamethasone (or equivalent of \> 10 mg prednisone) per day at time of registration * Participants must not have symptomatic central nervous system (CNS) metastases * Participants must not have known or suspected leptomeningeal disease * Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed \>= 6 months prior to registration * Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study * Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed \>= 24 weeks prior to registration and participants have recovered from all prior toxicities to =\< grade 1. * Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration * Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 \[IL-2\] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration * Participants must not have had history of known severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide * Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone \[GnRH\] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted. * Participants must be \>= 18 years of age * Participants must have a Zubrod performance status of =\< 2 within 28 days prior to registration * Participants must have a complete medical history and physical exam within 28 days prior to registration * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Hemoglobin \>= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Platelet count \>= 100 x 10\^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Serum total bilirubin =\< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Adequate renal function as defined by any 1 of the following: 1) Measured creatinine clearance (CL) \> 50 mL/min OR 2) Calculated creatinine CL \> 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Participants must not have uncontrolled or symptomatic hypercalcemia (\> 1.5 mmol/L ionized calcium or calcium \> 12 mg/dL or corrected serum calcium \> ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned * Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of \> 20 mg of hydrocortisone per day) or any other form of immunosuppressive therapy within 14 days prior to registration * Participants must not have active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions: * Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study * Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met: * Rash must cover \< 10% of body surface area * Disease is well controlled at baseline and requires only low-potency topical corticosteroids * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months * Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Participants must not have significant cardiovascular disease, such as New York Heart Association class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina * Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery * Participants must not have severe infections (i.e., Common Terminology Criteria for Adverse Events \[CTCAE\] grade \>= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia * Participants must not have known active tuberculosis * Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated * Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration * Participants must not have prior allogeneic bone marrow transplantation or solid organ transplant * Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist \[registered trademark\]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab * Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen * Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Conditions

Advanced Extrapulmonary Neuroendocrine Carcinoma Metastatic Extrapulmonary Neuroendocrine Carcinoma Recurrent Extrapulmonary Neuroendocrine Carcinoma Unresectable Extrapulmonary Neuroendocrine Carcinoma

Locations

  • Alaska Women's Cancer Care — Anchorage, Alaska, United States
  • Cancer Center at Saint Joseph's — Phoenix, Arizona, United States
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona, United States
  • Kaiser Permanente-Anaheim — Anaheim, California, United States
  • Sutter Auburn Faith Hospital — Auburn, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California, United States
  • Kaiser Permanente-Baldwin Park — Baldwin Park, California, United States
  • Kaiser Permanente-Bellflower — Bellflower, California, United States
  • Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California, United States
  • Mercy Cancer Center - Carmichael — Carmichael, California, United States
  • Mercy San Juan Medical Center — Carmichael, California, United States
  • Mercy Cancer Center - Elk Grove — Elk Grove, California, United States
  • Kaiser Permanente-Fontana — Fontana, California, United States
  • Palo Alto Medical Foundation-Fremont — Fremont, California, United States
  • Kaiser Permanente South Bay — Harbor City, California, United States
  • Kaiser Permanente-Irvine — Irvine, California, United States
  • Kaiser Permanente Los Angeles Medical Center — Los Angeles, California, United States
  • Kaiser Permanente West Los Angeles — Los Angeles, California, United States
  • Memorial Medical Center — Modesto, California, United States
  • Palo Alto Medical Foundation-Camino Division — Mountain View, California, United States
  • Kaiser Permanente-Ontario — Ontario, California, United States
  • Palo Alto Medical Foundation Health Care — Palo Alto, California, United States
  • Kaiser Permanente - Panorama City — Panorama City, California, United States
  • Kaiser Permanente-Riverside — Riverside, California, United States
  • Mercy Cancer Center - Rocklin — Rocklin, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Roseville — Roseville, California, United States
  • Sutter Roseville Medical Center — Roseville, California, United States
  • Mercy Cancer Center - Sacramento — Sacramento, California, United States
  • Sutter Medical Center Sacramento — Sacramento, California, United States
  • Kaiser Permanente-San Diego Zion — San Diego, California, United States
  • California Pacific Medical Center-Pacific Campus — San Francisco, California, United States
  • Kaiser Permanente-San Marcos — San Marcos, California, United States
  • Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California, United States
  • Sutter Pacific Medical Foundation — Santa Rosa, California, United States
  • Palo Alto Medical Foundation-Sunnyvale — Sunnyvale, California, United States
  • Sutter Solano Medical Center/Cancer Center — Vallejo, California, United States
  • Woodland Memorial Hospital — Woodland, California, United States
  • Kaiser Permanente-Woodland Hills — Woodland Hills, California, United States
  • AdventHealth Porter — Denver, Colorado, United States
  • AdventHealth Littleton — Littleton, Colorado, United States
  • AdventHealth Parker — Parker, Colorado, United States
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut, United States
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut, United States
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut, United States
  • Yale University — New Haven, Connecticut, United States
  • Yale-New Haven Hospital North Haven Medical Center — North Haven, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Long Ridge — Stamford, Connecticut, United States
  • Smilow Cancer Hospital-Torrington Care Center — Torrington, Connecticut, United States
  • Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut, United States
  • Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut, United States
  • Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut, United States
  • Holy Cross Hospital — Fort Lauderdale, Florida, United States
  • Mayo Clinic in Florida — Jacksonville, Florida, United States
  • Moffitt Cancer Center — Tampa, Florida, United States
  • Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii, United States
  • Queen's Cancer Cenrer - POB I — Honolulu, Hawaii, United States
  • Queen's Medical Center — Honolulu, Hawaii, United States
  • Straub Clinic and Hospital — Honolulu, Hawaii, United States
  • University of Hawaii Cancer Center — Honolulu, Hawaii, United States
  • Queen's Cancer Center - Kuakini — Honolulu, Hawaii, United States
  • Hawaii Cancer Care - Westridge — ‘Aiea, Hawaii, United States
  • Pali Momi Medical Center — ‘Aiea, Hawaii, United States
  • The Queen's Medical Center - West Oahu — ‘Ewa Beach, Hawaii, United States
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho, United States
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho, United States
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho, United States
  • Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho, United States
  • Rush-Copley Medical Center — Aurora, Illinois, United States
  • Centralia Oncology Clinic — Centralia, Illinois, United States
  • Northwestern University — Chicago, Illinois, United States
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois, United States
  • Carle at The Riverfront — Danville, Illinois, United States
  • Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois, United States
  • Decatur Memorial Hospital — Decatur, Illinois, United States
  • Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois, United States
  • Carle Physician Group-Effingham — Effingham, Illinois, United States
  • Crossroads Cancer Center — Effingham, Illinois, United States
  • Northwestern Medicine Cancer Center Delnor — Geneva, Illinois, United States
  • Northwestern Medicine Glenview Outpatient Center — Glenview, Illinois, United States
  • Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois, United States
  • Ingalls Memorial Hospital — Harvey, Illinois, United States
  • Northwestern Medicine Lake Forest Hospital — Lake Forest, Illinois, United States
  • Carle Physician Group-Mattoon/Charleston — Mattoon, Illinois, United States
  • SSM Health Good Samaritan — Mount Vernon, Illinois, United States
  • UC Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois, United States
  • Carle BroMenn Medical Center — Normal, Illinois, United States
  • Carle Cancer Institute Normal — Normal, Illinois, United States
  • Cancer Care Center of O'Fallon — O'Fallon, Illinois, United States
  • Northwestern Medicine Orland Park — Orland Park, Illinois, United States
  • University of Chicago Medicine-Orland Park — Orland Park, Illinois, United States
  • UW Health Carbone Cancer Center Rockford — Rockford, Illinois, United States
  • Southern Illinois University School of Medicine — Springfield, Illinois, United States
  • Springfield Clinic — Springfield, Illinois, United States
  • Springfield Memorial Hospital — Springfield, Illinois, United States
  • Carle Cancer Center — Urbana, Illinois, United States
  • Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois, United States
  • Rush-Copley Healthcare Center — Yorkville, Illinois, United States
  • UChicago Medicine Northwest Indiana — Crown Point, Indiana, United States
  • Mary Greeley Medical Center — Ames, Iowa, United States
  • McFarland Clinic - Ames — Ames, Iowa, United States
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa, United States
  • McFarland Clinic - Boone — Boone, Iowa, United States
  • Saint Anthony Regional Hospital — Carroll, Iowa, United States
  • Mercy Cancer Center-West Lakes — Clive, Iowa, United States
  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa, United States
  • Greater Regional Medical Center — Creston, Iowa, United States
  • Iowa Methodist Medical Center — Des Moines, Iowa, United States
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa, United States
  • Broadlawns Medical Center — Des Moines, Iowa, United States
  • Mercy Medical Center - Des Moines — Des Moines, Iowa, United States
  • UI Health Care Mission Cancer and Blood - Laurel Clinic — Des Moines, Iowa, United States
  • McFarland Clinic - Trinity Cancer Center — Fort Dodge, Iowa, United States
  • McFarland Clinic - Jefferson — Jefferson, Iowa, United States
  • McFarland Clinic - Marshalltown — Marshalltown, Iowa, United States
  • UI Health Care Mission Cancer and Blood - Waukee Clinic — Waukee, Iowa, United States
  • Mercy Medical Center-West Lakes — West Des Moines, Iowa, United States
  • LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana, United States
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana, United States
  • East Jefferson General Hospital — Metairie, Louisiana, United States
  • LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana, United States
  • University Medical Center New Orleans — New Orleans, Louisiana, United States
  • Lahey Clinic — Burlington, Massachusetts, United States
  • Lahey Clinic Peabody — Peabody, Massachusetts, United States
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan, United States
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States
  • Bronson Battle Creek — Battle Creek, Michigan, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan, United States
  • Trinity Health Medical Center - Brighton — Brighton, Michigan, United States
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan, United States
  • Trinity Health Medical Center - Canton — Canton, Michigan, United States
  • Chelsea Hospital — Chelsea, Michigan, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan, United States
  • Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan, United States
  • Corewell Health Dearborn Hospital — Dearborn, Michigan, United States
  • Henry Ford Medical Center-Fairlane — Dearborn, Michigan, United States
  • Wayne State University/Karmanos Cancer Institute — Detroit, Michigan, United States
  • Henry Ford Hospital — Detroit, Michigan, United States
  • Henry Ford Health Saint John Hospital — Detroit, Michigan, United States
  • Henry Ford River District Hospital — East China Township, Michigan, United States
  • Weisberg Cancer Treatment Center — Farmington Hills, Michigan, United States
  • Corewell Health Farmington Hills Hospital — Farmington Hills, Michigan, United States
  • Cancer Hematology Centers - Flint — Flint, Michigan, United States
  • Genesee Hematology Oncology PC — Flint, Michigan, United States
  • Genesys Hurley Cancer Institute — Flint, Michigan, United States
  • Hurley Medical Center — Flint, Michigan, United States
  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan, United States
  • Trinity Health Grand Rapids Hospital — Grand Rapids, Michigan, United States
  • Henry Ford Saint John Hospital - Academic — Grosse Pointe Woods, Michigan, United States
  • Henry Ford Saint John Hospital - Breast — Grosse Pointe Woods, Michigan, United States
  • Henry Ford Saint John Hospital - Van Elslander — Grosse Pointe Woods, Michigan, United States
  • Allegiance Health — Jackson, Michigan, United States
  • Bronson Methodist Hospital — Kalamazoo, Michigan, United States
  • West Michigan Cancer Center — Kalamazoo, Michigan, United States
  • Karmanos Cancer Institute at McLaren Greater Lansing — Lansing, Michigan, United States
  • Trinity Health Saint Mary Mercy Livonia Hospital — Livonia, Michigan, United States
  • Henry Ford Saint John Hospital - Macomb Medical — Macomb, Michigan, United States
  • Henry Ford Warren Hospital - Breast Macomb — Macomb, Michigan, United States
  • Trinity Health Muskegon Hospital — Muskegon, Michigan, United States
  • Corewell Health Lakeland Hospitals - Niles Hospital — Niles, Michigan, United States
  • Cancer and Hematology Centers of Western Michigan - Norton Shores — Norton Shores, Michigan, United States
  • Henry Ford Medical Center-Columbus — Novi, Michigan, United States
  • Trinity Health Saint Joseph Mercy Oakland Hospital — Pontiac, Michigan, United States
  • Corewell Health Reed City Hospital — Reed City, Michigan, United States
  • Corewell Health William Beaumont University Hospital — Royal Oak, Michigan, United States
  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center — Saint Joseph, Michigan, United States
  • Corewell Health Lakeland Hospitals - Saint Joseph Hospital — Saint Joseph, Michigan, United States
  • Munson Medical Center — Traverse City, Michigan, United States
  • Corewell Health Beaumont Troy Hospital — Troy, Michigan, United States
  • Henry Ford Health Warren Hospital — Warren, Michigan, United States
  • Henry Ford Madison Heights Hospital - Breast — Warren, Michigan, United States
  • Henry Ford Warren Hospital - GLCMS — Warren, Michigan, United States
  • Henry Ford West Bloomfield Hospital — West Bloomfield, Michigan, United States
  • Henry Ford Wyandotte Hospital — Wyandotte, Michigan, United States
  • University of Michigan Health - West — Wyoming, Michigan, United States
  • Huron Gastroenterology PC — Ypsilanti, Michigan, United States
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus — Ypsilanti, Michigan, United States
  • Minnesota Oncology - Burnsville — Burnsville, Minnesota, United States
  • Saint Luke's Hospital of Duluth — Duluth, Minnesota, United States
  • Fairview Southdale Hospital — Edina, Minnesota, United States
  • Minnesota Oncology - Edina — Edina, Minnesota, United States
  • Abbott-Northwestern Hospital — Minneapolis, Minnesota, United States
  • Hennepin County Medical Center — Minneapolis, Minnesota, United States
  • Mayo Clinic in Rochester — Rochester, Minnesota, United States
  • Park Nicollet Clinic - Saint Louis Park — Saint Louis Park, Minnesota, United States
  • Regions Hospital — Saint Paul, Minnesota, United States
  • United Hospital — Saint Paul, Minnesota, United States
  • Saint Francis Regional Medical Center — Shakopee, Minnesota, United States
  • Saint Francis Medical Center — Cape Girardeau, Missouri, United States
  • Mercy Hospital Joplin — Joplin, Missouri, United States
  • Mercy Hospital Springfield — Springfield, Missouri, United States
  • CoxHealth South Hospital — Springfield, Missouri, United States
  • Mercy Hospital South — St Louis, Missouri, United States
  • Billings Clinic Cancer Center — Billings, Montana, United States
  • Saint Vincent Frontier Cancer Center — Billings, Montana, United States
  • Benefis Sletten Cancer Institute — Great Falls, Montana, United States
  • Logan Health Medical Center — Kalispell, Montana, United States
  • Community Medical Center — Missoula, Montana, United States
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire, United States
  • Roswell Park Cancer Institute — Buffalo, New York, United States
  • Mount Sinai Hospital — New York, New York, United States
  • Stony Brook University Medical Center — Stony Brook, New York, United States
  • Duke Cancer Center Cary — Cary, North Carolina, United States
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina, United States
  • Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina, United States
  • Levine Cancer Institute-SouthPark — Charlotte, North Carolina, United States
  • Atrium Health University City/LCI-University — Charlotte, North Carolina, United States
  • Levine Cancer Institute-Ballantyne — Charlotte, North Carolina, United States
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina, United States
  • Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina, United States
  • Duke University Medical Center — Durham, North Carolina, United States
  • Levine Cancer Institute-Gaston — Gastonia, North Carolina, United States
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina, United States
  • Southeastern Medical Oncology Center-Jacksonville — Jacksonville, North Carolina, United States
  • FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina, United States
  • Duke Cancer Center Raleigh — Raleigh, North Carolina, United States
  • Atrium Health Cleveland/LCI-Cleveland — Shelby, North Carolina, United States
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
  • Toledo Clinic Cancer Centers-Toledo — Toledo, Ohio, United States
  • Cancer Centers of Southwest Oklahoma Research — Lawton, Oklahoma, United States
  • University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States
  • Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma, United States
  • Saint Charles Health System — Bend, Oregon, United States
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon, United States
  • Providence Newberg Medical Center — Newberg, Oregon, United States
  • Providence Willamette Falls Medical Center — Oregon City, Oregon, United States
  • Providence Portland Medical Center — Portland, Oregon, United States
  • Providence Saint Vincent Medical Center — Portland, Oregon, United States
  • WellSpan Medical Oncology and Hematology — Chambersburg, Pennsylvania, United States
  • Ephrata Cancer Center — Ephrata, Pennsylvania, United States
  • Adams Cancer Center — Gettysburg, Pennsylvania, United States
  • WellSpan Medical Oncology and Hematology — Hanover, Pennsylvania, United States
  • Sechler Family Cancer Center — Lebanon, Pennsylvania, United States
  • Cancer Care Associates of York — York, Pennsylvania, United States
  • WellSpan Health-York Cancer Center — York, Pennsylvania, United States
  • Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island, United States
  • Medical University of South Carolina — Charleston, South Carolina, United States
  • Levine Cancer Institute-Rock Hill — Rock Hill, South Carolina, United States
  • Rapid City Regional Hospital — Rapid City, South Dakota, United States
  • Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee, United States
  • Parkland Memorial Hospital — Dallas, Texas, United States
  • UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas, United States
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas, United States
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas, United States
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas, United States
  • Ben Taub General Hospital — Houston, Texas, United States
  • UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas, United States
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah, United States
  • Dartmouth Cancer Center - North — Saint Johnsbury, Vermont, United States
  • Fred Hutchinson Cancer Center — Seattle, Washington, United States
  • University of Washington Medical Center - Montlake — Seattle, Washington, United States
  • United Hospital Center — Bridgeport, West Virginia, United States
  • West Virginia University Healthcare — Morgantown, West Virginia, United States
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin, United States
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin, United States
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin, United States
  • Medical College of Wisconsin — Milwaukee, Wisconsin, United States
  • Marshfield Medical Center - Minocqua — Minocqua, Wisconsin, United States
  • Marshfield Medical Center-Rice Lake — Rice Lake, Wisconsin, United States
  • Marshfield Medical Center-River Region at Stevens Point — Stevens Point, Wisconsin, United States
  • Marshfield Medical Center - Weston — Weston, Wisconsin, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record